Evan Seigerman
Stock Analyst at BMO Capital
(3.81)
# 750
Out of 4,761 analysts
140
Total ratings
53.26%
Success rate
8.28%
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Market Perform | $156 → $139 | $140.64 | -1.17% | 26 | Feb 13, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $110 → $115 | $109.95 | +4.59% | 15 | Feb 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $566 → $520 | $484.24 | +7.38% | 14 | Dec 20, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $57 → $61 | $55.83 | +9.26% | 11 | Nov 12, 2024 | |
| INCY Incyte | Reiterates: Underperform | $48 → $52 | $72.11 | -27.89% | 12 | Oct 30, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $128 → $114 | $120.69 | -5.54% | 14 | Oct 17, 2024 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $1,001 → $1,101 | $873.68 | +26.02% | 8 | Aug 9, 2024 | |
| IRON Disc Medicine | Reiterates: Outperform | $50 → $70 | $54.53 | +28.37% | 5 | Jun 17, 2024 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $23.77 | +68.31% | 1 | Feb 28, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $40 | $13.98 | +186.12% | 1 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $757 → $788 | $700.33 | +12.52% | 17 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $8 → $2.5 | $2.21 | +13.12% | 2 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $263 → $243 | $303.01 | -19.80% | 6 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $11.63 | +3.18% | 2 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $26.30 | +128.14% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $27 | $1.39 | +1,842.45% | 2 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $30 | $2.76 | +986.96% | 3 | May 12, 2020 |
Biogen
Feb 13, 2025
Maintains: Market Perform
Price Target: $156 → $139
Current: $140.64
Upside: -1.17%
Gilead Sciences
Feb 12, 2025
Maintains: Outperform
Price Target: $110 → $115
Current: $109.95
Upside: +4.59%
Vertex Pharmaceuticals
Dec 20, 2024
Maintains: Outperform
Price Target: $566 → $520
Current: $484.24
Upside: +7.38%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Market Perform
Price Target: $57 → $61
Current: $55.83
Upside: +9.26%
Incyte
Oct 30, 2024
Reiterates: Underperform
Price Target: $48 → $52
Current: $72.11
Upside: -27.89%
Neurocrine Biosciences
Oct 17, 2024
Maintains: Market Perform
Price Target: $128 → $114
Current: $120.69
Upside: -5.54%
Eli Lilly and Company
Aug 9, 2024
Maintains: Outperform
Price Target: $1,001 → $1,101
Current: $873.68
Upside: +26.02%
Disc Medicine
Jun 17, 2024
Reiterates: Outperform
Price Target: $50 → $70
Current: $54.53
Upside: +28.37%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $23.77
Upside: +68.31%
Replimune Group
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $13.98
Upside: +186.12%
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $700.33
Upside: +12.52%
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $2.21
Upside: +13.12%
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $303.01
Upside: -19.80%
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $11.63
Upside: +3.18%
Nov 19, 2021
Initiates: Outperform
Price Target: $60
Current: $26.30
Upside: +128.14%
Aug 13, 2021
Maintains: Outperform
Price Target: $30 → $27
Current: $1.39
Upside: +1,842.45%
May 12, 2020
Maintains: Outperform
Price Target: $13 → $30
Current: $2.76
Upside: +986.96%